Rare disease is also called "orphan disease", and the World Health Organization (WHO) defines the disease with an incidence rate of 0.65 ‰–1 ‰ as a rare disease. However, only about 1% of rare diseases have effective therapeutic drugs. Especially in Rare Disease research, monoclonal anti-tumor drugs have been widely studies because of the high specificity, low incidence of adverse reactions, and good patient tolerance! Currently, several monoclonal antibodies have been approved for the treatment of rare diseases (Click to See Popular Targets for Targets of Monoclonal Antibody Drugs).
CUSABIO offers a one-stop The Lead Antibody Discovery Service assists in this process, which is being widely used to efficiently identify promising candidates for new antibody drug.
General Steps of Lead Selection of Antibody Drug Discovery
CUSABIO has been specialized in the production of transmembrane protein for more than 13 years, so we are confident we can prepare the "right" antigen for the lead selection of antibody drug discovery. Mostly, CUSABIO has good experience in projects of lead selection, so we are sure we can meet the various demands of our customers under mutiple options of technology.
Popular Research Targets of Monoclonal Antibody Drugs
Drug targets are the sites where drugs bind to biological macromolecules of the body, which can regulate physiological function or achieve the purpose of treating diseases by specifically binding to specific drugs. The following table lists the popular targets for research and development in the monoclonal antibody field.
CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.
Kit
Protein
Antibody
Molecular Biology
CUSABIO TECHNOLOGY LLC
Postal Address: 7505 Fannin St Ste 610-322 Houston, TX 77054, USA
